Fundz

Allogene Therapeutics, Inc. reported raising $412 Million in an initial SEC Form D filing, from an offering of $412 Million

PUBLIC · ALLOApr 19, 2018

Amount Raised

$412 Million

$412 Million sold, per SEC Form D (first sale Apr 19, 2018)

Round Type

Venture

San FranciscoBiotechnologyHealth CareTherapeutics

Quick answer

Allogene Therapeutics, Inc. raised $412 Million in a funding round, dated April 19, 2018. Allogene Therapeutics, Inc. is based in San Francisco, California, United States.

How much did Allogene Therapeutics, Inc. raise?
Allogene Therapeutics, Inc. raised $412 Million in a funding round on April 19, 2018.
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
Where is Allogene Therapeutics, Inc. based and how big is it?
Allogene Therapeutics, Inc. is based in San Francisco, California, United States.
Who are the decision-makers at Allogene Therapeutics, Inc?
Fundz holds 1 contact at Allogene Therapeutics, Inc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Allogene Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Vergent Bioscience raised $8.7M on June 1, 2018.
  • IRulya Therapeutics Inc. raised $84M on May 31, 2018.
  • Acasti raised $373K on May 25, 2018.
  • Scipher Medicine raised $795K (Seed) on May 24, 2018.
  • Kodiak Sciences raised $30M on May 22, 2018.
  • Strata Oncology raised $12M on May 11, 2018.

Who to call at Allogene Therapeutics, Inc., and when

A new round usually means Allogene Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Allogene Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Allogene Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Allogene Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Allogene Therapeutics, Inc.

Location

270 LITTLEFIELD AVE

San Francisco, California, United States

About

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Allogene Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Allogene Therapeutics, Inc.'s next move

See what Strategic adds

Allogene Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.